Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLASS-BD: Biomarkers in Affective Disorders
NCT05480150Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Nov 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of quetiapine, lurasidone and escitalopram in bipolar disorder (BD) and major depressive disorder (MDD) (3 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Montgomery-Asberg Depression Rating Scale. Started Nov 2021; status: recruiting.
02
Drugs
quetiapinelurasidoneescitalopram
03
Conditions
bipolar disorder (BD)major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05480150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05480150.